Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin

AbstractLefamulin  (Xenleta) has been approved by the US FDA for the treatment of community-acquired bacterial pneumonia (CABP). It may be taken intravenously or orally and has activity against a broad range of pulmonary pathogens, includingStreptococcus pneumoniae, Haemophilus influenzae,Mycoplasma pneumoniae,Legionella pneumophila, andChlamydophila pneumonia, as well as methicillin-resistantStaphylococcus aureus and vancomycin-resistantEnterococcus faecium. Lefamulin has an adverse effect profile that is similar to other antimicrobial agents commonly used to treat CABP. Despite these promising features, the use of lefamulin remains limited in clinical practice. However, given the rise of antibiotic-resistant organisms, this may soon change. This review examines what is known about the pharmacokinetics and pharmacodynamics of lefamulin and looks ahead to its potential applications in clinical practice, including the treatment of sexually transmitted infections such as multidrug-resistant  Mycoplasma genitalium, as well as its role as a synergistic agent used in combination with other antimicrobials in the treatment of drug-resistant organisms.

Source: Clinical Pharmacokinetics - July 13, 2021 Category: Drugs & Pharmacology Source Type: research